Page last updated: 2024-11-01

niclosamide and Obesity

niclosamide has been researched along with Obesity in 3 studies

Niclosamide: An antihelmintic that is active against most tapeworms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p48)
niclosamide : A secondary carboxamide resulting from the formal condensation of the carboxy group of 5-chlorosalicylic acid with the amino group of 2-chloro-4-nitroaniline. It is an oral anthelmintic drug approved for use against tapeworm infections.

Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).

Research Excerpts

ExcerptRelevanceReference
"Niclosamide piperazine salt may hold the promise to become an alternative to NEN as a drug lead for the treatment of obesity and T2D."7.91Niclosamide piperazine prevents high-fat diet-induced obesity and diabetic symptoms in mice. ( Alasadi, A; Guo, J; Huang, Q; Jin, S; Tao, H, 2019)
"To assess the anti-obesity effects of niclosamide on mice with induced obesity."7.85Niclosamide as an anti-obesity drug: an experimental study. ( Al-Gareeb, AI; Aljubory, KD; Alkuraishy, HM, 2017)
"Niclosamide piperazine salt may hold the promise to become an alternative to NEN as a drug lead for the treatment of obesity and T2D."3.91Niclosamide piperazine prevents high-fat diet-induced obesity and diabetic symptoms in mice. ( Alasadi, A; Guo, J; Huang, Q; Jin, S; Tao, H, 2019)
"To assess the anti-obesity effects of niclosamide on mice with induced obesity."3.85Niclosamide as an anti-obesity drug: an experimental study. ( Al-Gareeb, AI; Aljubory, KD; Alkuraishy, HM, 2017)
"Metabolic disorders such as type 2 diabetes, fatty liver disease, hyperlipidemia, and obesity commonly co-occur but clinical treatment options do not effectively target all disorders."2.44Head-to-head comparison of BAM15, semaglutide, rosiglitazone, NEN, and calorie restriction on metabolic physiology in female db/db mice. ( Alexopoulos, SJ; Beretta, M; Byrne, FL; Cantley, J; Chen, SY; Garcia, CJ; Hoehn, KL; Larance, M; Olzomer, EM; Philp, A; Salamoun, JM; Santos, WL; Shah, DP; Smith, GC; Turner, N, 2024)

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (66.67)24.3611
2020's1 (33.33)2.80

Authors

AuthorsStudies
Chen, SY1
Beretta, M1
Olzomer, EM1
Alexopoulos, SJ1
Shah, DP1
Byrne, FL1
Salamoun, JM1
Garcia, CJ1
Smith, GC1
Larance, M1
Philp, A1
Turner, N1
Santos, WL1
Cantley, J1
Hoehn, KL1
Guo, J1
Tao, H1
Alasadi, A1
Huang, Q1
Jin, S1
Al-Gareeb, AI1
Aljubory, KD1
Alkuraishy, HM1

Other Studies

3 other studies available for niclosamide and Obesity

ArticleYear
Head-to-head comparison of BAM15, semaglutide, rosiglitazone, NEN, and calorie restriction on metabolic physiology in female db/db mice.
    Biochimica et biophysica acta. Molecular basis of disease, 2024, Volume: 1870, Issue:1

    Topics: Animals; Caloric Restriction; Diabetes Mellitus, Type 2; Ethanolamine; Ethanolamines; Female; Mice;

2024
Niclosamide piperazine prevents high-fat diet-induced obesity and diabetic symptoms in mice.
    Eating and weight disorders : EWD, 2019, Volume: 24, Issue:1

    Topics: Animals; Diabetes Mellitus, Type 2; Diet, High-Fat; Disease Models, Animal; Insulin Resistance; Mice

2019
Niclosamide as an anti-obesity drug: an experimental study.
    Eating and weight disorders : EWD, 2017, Volume: 22, Issue:2

    Topics: Animals; Anti-Obesity Agents; Blood Glucose; Body Weight; Cholesterol; Diet, High-Fat; Eating; Insul

2017